Skip to main content
NAGE logo

NAGE · Niagen Bioscience, Inc.

Track NAGE — free
$1.86 -0.08 (-4.12%)
Market Cap
$148.10M
Shares
79.20M
Volume · Nov 19 490.98K Avg daily vol (3M) 506.37K

Price & Indicators

Close$1.87 Open$1.92 Day$1.84–1.93 52W close$1.87–7.04 Avg vol 30d549K Short int4.3M · 5.5% of shares · 8.9d Short vol39% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Mar 3, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 4
Earnings call
Net sales reach $27.2 million despite a $1.2 million loss

Niagen Bioscience reported third-quarter net sales of $27.2 million, a net loss of $1.2 million, and $450,000 of adjusted EBITDA. It generated approximately $2.6 million in operating cash flow and ended with $69.5 million in cash and no debt.

4 source passages
Earlier today, Niagen Bioscience issued a press release announcing its financial results for the third quarter of 2026. In the third quarter of 2026, net sales were $27.2 million, with TruNiagen contributing $23.3 million, a decrease of 10% or $2.7 million year-over-year. And finally, net loss was negative $1.2 million, or $0.01 per diluted share, compared to net income of $0.06 per diluted share in the third quarter of 2025. In the third quarter, we generated approximately $2.6 million in positive operating cash flow and $450,000 of adjusted EBITDA. We ended the quarter with $69.5 million in cash, no debt, and $83.3 million in working capital, a $600,000 increase. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net sales fall 20% as net loss emerges

Niagen Bioscience reported a 20% decline in net sales for the three months ended September 30, 2026 and a net loss. Cash and cash equivalents totaled approximately $69.5 million as of September 30, 2026.

Revenue $27.19M ▼ 20.0% Net loss $1.17M Diluted EPS -$0.01
Read from the MD&A section
6 source passages
Unless otherwise indicated or unless the context otherwise requires, all references in this document to “we,” “us,” “our,” “Company,” “Niagen Bioscience” and similar expressions refer to Niagen Bioscience, Inc., and depending on the context, its subsidiaries. Three Months Ended September 30, 2026 | 2025 | % Change Total net sales | 27,192 | 33,986 | (20)% Net income (loss) | (1,173) | 4,578 As of September 30, 2026, our cash and cash equivalents totaled approximately $69.5 million, of which $69.4 million was unrestricted. Open the document at this passage
Nov 4
Current report 8-K
Third-quarter sales $27.2 million, net loss $1.2 million

Niagen Bioscience reported third-quarter net sales of $27.2 million, including $23.3 million from Tru Niagen, a net loss of $1.2 million, and $2.6 million in operating cash flow. It ended the quarter with $69.5 million in cash and cash equivalents.

Financial results, Regulation FD disclosure
4 source passages
Total net sales of $27.2 million, including $23.3 million from Tru Niagen®. Net loss of $1.2 million Generated $2.6 million of operating cash flow The Company ended the quarter with $69.5 million in cash and cash equivalents Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$122.29M
Trailing 12 months
Net income (TTM)
$10.24M
Trailing 12 months
Revenue growth YoY
-20.0%
Year over year
Operating margin
3.9%
Trailing 12 months
P / E (TTM)
16.2
Trailing earnings · reciprocal yield 6.2%
FCF yield
—
TTM · current market cap
Return on invested capital
32.6%
Trailing 12 months
Net cash
$69.51M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-8.6%
Year over year · fewer shares
Price change (1Y)
-71.7%
Trailing year
Short interest
5.5%
Latest settlement · 8.9 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. Cash generation, a debt-free balance sheet, direct website growth, broader distribution, skincare expansion, and research advances support the outlook for growth. Third-quarter sales, profitability, gross margin, and adjusted EBITDA weakened, while marketing intensity, litigation-related G&A, ingredient pressure, and expected operating-expense increases remain headwinds.

Bullish
  • + Tru Niagen distribution expanded through Walmart.com and nearly 300 GNC and Sam's Club locations across 44 states.
Bearish
  • − Gross margin declined to 62.9% from 64.5% due to changes in product and business mix.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −49%
below
Price vs 50-day avg −27%
below
RSI (14) 31
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −26%
trailing
6-month return −48%
trailing
YTD return −71%
this year
Relative strength −43%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +16 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.49% of shares out · ▲ +4.2% MoM · 8.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
125 holders — mid 3-yr range
Squeeze score 57
elevated · 0–100
Fundamentals
Excellent
Revenue growth +30%
Y/Y
Gross margin 64%
expanding
EPS growth +82%
Y/Y
Free cash flow $12.8M
Valuation P/E 15.6
below peers
Buyback $14.6M
remaining
Quant / Vol
risk profile
Very High
Volatility 51%
annualized · 1-yr
Max drawdown −73%
past year
ATR 6.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 4, 2026
For the full year 2026
Direct website revenues 15% – 20%
Overall e-commerce 5%
2026 Outlook
E-commerce growth 5%
Previous outlook earlier release · from the 8-K filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

E-commerce business · full year 2026 10% – 15%
E-commerce business to grow year-over-year · full year 2026 10% – 15%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−49% Bearish
Price vs 50-day avg
−27% Bearish
RSI (14)
31 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +16 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.49% of shares out · ▲ +4.2% MoM · 8.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
125 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 0% Range high $7
vs 200-day avg -49% vs 50-day avg -27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
GAAP → non-GAAP reconciliation
GAAP Net income 963K
-372K Interest income, net
+106K Provision for income taxes
+117K Depreciation
+174K Amortization of intangibles
+179K Noncash lease expense
+1.72M Share-based compensation
+144K Severance and restructuring
+3K Gain on sale of operating segment
= Adjusted EBITDA 3.04M
Common stock repurchased $2.8M the quarter —
Cross-border sales into China increase $1M the three months ended June 30, 2026 filing —
Direct to consumer sales on the Company’s website growth 23% Q2 2026 —
E-commerce channel sales growth $2.5M the three months ended June 30, 2026 filing —
E-Commerce net sales 20.5M Q2 2026 —
Gross margin 64.8% Q2 2026 —
Sales to A.S. Watson Group decrease $2.3M the three months ended June 30, 2026 filing —
Shares repurchased under the Share Repurchase Program 683,419 the three months ended June 30, 2026 filing —
Total cash provided by operations $1.6M six months ended June 30, 2026 —
Tru Niagen® sales increase $1.5M the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Packaged Foods — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NAGE
Niagen Bioscience, Inc.
this stock
$148.10M -70.6% +29.9% 15.6 5.5%
JBS
Jbs N.V.
$39.01B -17.8% — — 1.3%
KHC
Kraft Heinz Co
$29.50B +2.8% -0.1% — 8.7%
GIS
General Mills Inc
$18.44B -25.8% +4.1% — 7.0%
SJM
J M SMUCKER Co
$14.02B +34.2% +3.7% — 2.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
125
% held
38.1%
Net QoQ
-1.7M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
125
View
Short & Settlement
Short Interest Rising
Shares short
4.3M
Days to cover
8.9d
Change
+173.5K sh
View
Short Volume
Short vol %
39%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
3.0K
Value
$7.4K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
44.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$129.4M
Net income (FY)
$17.4M
EPS diluted
$0.20
View
Buybacks
Authorized
$20.0M
Remaining
$14.6M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
16

Niagen Bioscience reported a 20% decline in net sales for the three months ended September 30, 2026 and a net loss. Cash and cash equivalents totaled approximately $69.5 million as of September 30, 2026.

View
Proposed Sales
Value
$230.0K
Shares
37.2K
Filed
Dec 13, 2024
View
Exempt Offerings
Offering
$3.1M
Filed
Oct 14, 2022
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 10, 2026
Last webcast
Nov 19, 2026
View
Investor Relations
Latest news
Niagen Bioscience to Present at t…
Published
Nov 16, 2026
Upcoming events
3
View

Performance

5D 20D 120D MTD YTD
NAGE -12.4% -25.8% -48.2% -19.7% -70.6%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -7.0% -19.5% -42.6% -14.5% -75.6%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$20.00M
Spent (derived)
$5.40M
Remaining
$14.60M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1386570 CUSIP 171077407 13F (30d) 129 filings 116 filers Visit website Investor relations